A higher percentage of CAP patients showed reduced CD3+, CD3+CD4+, reduced CD16+CD56+, reduced CD4+/CD8+ ratio, increased CD19+%, and normal CD3+CD4+% compared with the COVID-19 patients. This evidence concerns the gene NCAM1 and COVID-19.